Dr Lal PathLabs Expands Genomics Division with Illumina’s NovaSeq X Series

The new addition cements its leadership in next-generation sequencing (NGS), equipping DLPL to offer faster, AI-enabled genomic insights with heightened accuracy and clinical relevance.

Dr Lal PathLabs (DLPL) has enhanced its genomics infrastructure by incorporating Illumina’s NovaSeq X Series into its specialised genomics arm, Genevolve.

This strategic addition will enable DLPL to accelerate and refine the delivery of genomic research insights.

Powered by Illumina’s XLEAP-SBS chemistry, the NovaSeq X system offers high data output, sequencing accuracy, and improved operational efficiency.

According to the company, the latest innovation can process over 20,000 whole genomes annually, more than twice the capacity of its predecessor. This marks a significant leap in speed and scale for genetic sequencing. The platform is designed to unlock deeper biological insights and enable groundbreaking discoveries.

“With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence. This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape,” said Shankha Banerjee, CEO, Dr Lal PathLabs.

Since its launch in 2019, Genevolve has quickly established itself as a DNA-driven centre of excellence. The new addition cements its leadership in next-generation sequencing (NGS), equipping DLPL to offer faster, AI-enabled genomic insights with heightened accuracy and clinical relevance.

“At Genevolve, our mission has always been to push the boundaries of genomic innovation. Bringing the NovaSeq X Series into our portfolio is a testament to that commitment, combining the power of next-generation sequencing and AI to enable faster, more precise, and meaningful insights for better outcomes,” said Dr Vandana Lal, Executive Director, Dr Lal PathLabs Limited.

The NovaSeq X Series also marks a significant milestone in Illumina’s efforts to scale NGS access across India.

Premas Life Sciences, Illumina’s distribution partner in India, also reaffirmed its support.

“Our longstanding vision has been to accelerate India's adoption of next-generation sequencing technologies. We are proud to support Dr. Lal PathLabs in integrating the NovaSeq X platform into their genomics ecosystem, driving transformative research and innovation,” said Praveen Gupta, Managing Director, Premas Life Sciences.

Stay tuned for more such updates on Digital Health News